20 categories
Access
Coverage, cost, availability and geography — the practical barriers between a person and a legitimate supply.
70 topics · page 2 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
|
+147 | 156 | 18k | 3mo |
|
List price versus negotiated price versus what you pay
On the subject in the title: List price versus negotiated price versus what you pay Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires.…
|
+99 | 115 | 11k | 3mo |
|
[2026 update] Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+40 | 45 | 14k | 4mo |
|
Cost per delivered dose, which is the number that matters
Cost per delivered dose, which is the number that matters — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…
|
+54 | 59 | 30k | 4mo |
|
Revisiting: Language barriers in accessing a prescription abroad
Posting this under the heading it deserves: Revisiting: Language barriers in accessing a prescription abroad Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
|
+131 | 148 | 28k | 5mo |
|
Peer-to-peer review: what actually happens on the call — one year on
Peer-to-peer review: what actually happens on the call — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…
|
+2 | 6 | 41k | 5mo |
|
Appeal templates and why they are deliberately unemotional
Posting this under the heading it deserves: Appeal templates and why they are deliberately unemotional Everything below is what sits behind that. Documenting an access outcome, dated, because everything in…
|
+25 | 29 | 764 | 7mo |
|
Availability by country, dated, with primary sources — one year on
Availability by country, dated, with primary sources — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…
|
+7 | 11 | 850 | 7mo |
|
Substitution between formats during a shortage
On the subject in the title: Substitution between formats during a shortage Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
+114 | 123 | 47k | 7mo |
|
Personal import allowances, compared
On the subject in the title: Personal import allowances, compared Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of July 2026, in…
|
+5 | 9 | 3.2k | 7mo |
|
Documentation that materially improves an appeal's chances
Documentation that materially improves an appeal's chances — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…
|
+93 | 98 | 3.6k | 8mo |
|
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+72 | 81 | 6.9k | 8mo |
|
Managing an unplanned gap in supply — what changed since
On the subject in the title: Managing an unplanned gap in supply — what changed since Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+114 | 124 | 54k | 8mo |
|
Revisiting: Reading a denial letter as a specification for your appeal
Posting this under the heading it deserves: Revisiting: Reading a denial letter as a specification for your appeal Everything below is what sits behind that. A coverage question with the paperwork detail…
|
+125 | 138 | 9.4k | 10mo |
|
Appeal templates and why they are deliberately unemotional — one year on
Appeal templates and why they are deliberately unemotional — one year on Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because…
|
2 | 4.1k | 11mo | |
|
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
|
+6 | 10 | 41k | 11mo |
|
Coming back to: Official shortage notices and what they authorise
Official shortage notices and what they authorise Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+85 | 92 | 5.5k | 11mo |
|
Revisiting: List price versus negotiated price versus what you pay
Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is…
|
+24 | 28 | 50k | 12mo |
|
Reading a denial letter as a specification for your appeal
Reading a denial letter as a specification for your appeal Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that…
|
3 | 30k | 12mo | |
|
An appeal that failed, and what I would do differently
An appeal that failed, and what I would do differently Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
|
+4 | 8 | 125 | 12mo |
|
[2026 update] Documentation that materially improves an appeal's chances
On the subject in the title: Documentation that materially improves an appeal's chances Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
2 | 2.4k | 13mo | |
|
Pen wastage and its effect on real cost — the long version
Posting this under the heading it deserves: Pen wastage and its effect on real cost — the long version Everything below is what sits behind that. Documenting an access outcome, dated, because everything in…
|
2 | 34k | 13mo | |
|
Coming back to: Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this…
|
+21 | 25 | 55k | 13mo |
|
Cost per milligram, computed honestly across formats — a second dataset
Cost per milligram, computed honestly across formats — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…
|
2 | 27k | 13mo | |
|
[2026 update] An appeal that failed, and what I would do differently
Posting this under the heading it deserves: An appeal that failed, and what I would do differently Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
+152 | 159 | 2.5k | 13mo |
|
Price changes over 2025 and 2026, tabulated and dated
Posting this under the heading it deserves: Price changes over 2025 and 2026, tabulated and dated Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
+4 | 8 | 658 | 14mo |
|
Cost per milligram, computed honestly across formats — the long version
Cost per milligram, computed honestly across formats — the long version Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…
|
+111 | 124 | 24k | 14mo |
|
Coverage for the indication versus for the drug
Coverage for the indication versus for the drug — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
|
+70 | 79 | 18k | 14mo |
|
Second pass at: Cross-border purchase within the EU: the actual rules
Posting this under the heading it deserves: Second pass at: Cross-border purchase within the EU: the actual rules Everything below is what sits behind that. Documenting an access outcome, dated, because…
|
+135 | 139 | 8.7k | 16mo |
|
Coverage for the indication versus for the drug — a second dataset
On the subject in the title: Coverage for the indication versus for the drug — a second dataset Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is…
|
+46 | 50 | 41k | 16mo |